Mease, P. J., Chohan, S., Garcia Fructuoso, F. J., Gottlieb, A. B., Chou, R. C., Mendelsohn, A. M., & Luggen, M. E. (2020). Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis. SKIN The Journal of Cutaneous Medicine, 4(5), s43. https://doi.org/10.25251/skin.4.supp.43